The facility is anticipated to produce respiratory mRNA vaccines for Canadians in 2025 and improve domestic preparedness for future pandemics for all citizens of Canada
Moderna announces the completion of mRNA vaccine manufacturing plant in Canada. (Credit: CNW Group/ Moderna, Inc.)
American pharmaceutical major Moderna has completed the construction of its messenger RNA (mRNA) manufacturing facility in Laval, Quebec, Canada.
Assuming regulatory clearances and certifications, the facility should be prepared to produce respiratory mRNA vaccines for Canadians in 2025.
This will guarantee that all vaccines produced meet the highest standards of quality, safety, and efficacy, Moderna said.
The development of this site also advances Moderna’s strategic partnership with the federal government to enhance domestic preparedness for future pandemics for all citizens of Canada.
Additionally, the project is expected to create and promote high-skilled job possibilities.
The construction of the facility was financed in part by Investissement Québec, the Quebec government.
Moderna CEO Stéphane Bancel said: “With infectious diseases continuing to pose a significant health challenge, our mRNA platform can play a pivotal role against current and future threats.
“Canada’s role in global health is critical, and with this facility, Moderna is honoured to contribute to its robust scientific community and public health leadership in driving innovation and transformative medicine forward.”
Moderna’s dedication to environmentally sustainable practices is evident at this manufacturing facility.
Most of the power produced in Quebec comes from renewable resources, which supports Moderna’s goal of achieving net-zero emissions by 2030 in scopes 1 and 2.
The American drug maker intends to eliminate the use of fossil fuels in this new manufacturing site.
Infectious disorders, immuno-oncology, uncommon diseases, and autoimmune diseases are among the 45 therapeutic and vaccine programmes that Moderna presently has in development, nine of which are in the late stages of development.
Laval Mayor Stéphane Boyer said: ”Our Cité de la biotech of Laval is expanding phenomenally today as construction of the Moderna manufacturing plant is completed.
“The arrival of a major player in life sciences and health technologies in the Laval economic ecosystem is a sign of a dynamic city in action.
“Having a company of this magnitude on our territory is supporting our objective and vision of being a global leader where you can find quality facilities, vibrant living spaces and a qualified workforce.”